Skip to main content
Clinical Trials/JPRN-UMIN000026783
JPRN-UMIN000026783
Completed
N/A

A feasibility study of neoadjuvant chemotherapy with docetaxel+cisplatin+capecitabine (DCX) for HER2-negative gastric cancer with macroscopic type 4 and large type 3, or with multiple lymph node metastasis - A feasibility study of neoadjuvant chemotherapy with docetaxel+cisplatin+capecitabine (DCX) for HER2-negative gastric cancer with macroscopic type 4 and large type 3, or with multiple lymph node metastasis

agoya University0 sites20 target enrollmentMay 1, 2017
ConditionsGastric cancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Gastric cancer
Sponsor
agoya University
Enrollment
20
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 1, 2017
End Date
March 31, 2024
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
agoya University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) HER2 IHC 3\+, or IHC 2 and FISH\+ 2\) Uncontrolled diabetes 3\) Uncontrolled hypertension 4\) Unstable angina pectoris, or a history of myocardial infarction within six months 5\) Chronic lung disease: interstitial pneumonia, pulmonary fibrosis, or severe emphysema 6\) Synchronous cancers (except for cases whose prognositc facter is gastric cancer) 7\) Systemic infection requiring treatment 8\) Fever above 38 degree Celsius 9\) A possibility of pregnancy or during pregnancy, or lactating women 10\) Psychosis or psychotic symptoms 11\) Continuous systemic administration of steroids (oral or intravenous)

Outcomes

Primary Outcomes

Not specified

Similar Trials